PLK-activated TGF-β associates with resistance to combined immunotherapy and radiotherapy in metastatic pancreatic cancer

Liquid biopsy to track plasma kallikrein-activated TGF-β associates with resistance to combined immunotherapy and radiotherapy in metastatic pancreatic cancer

Introduction

Pancreatic ductual adenocarcinoma (PDAC) remains one of the deadliest malignancies with poor response to immune checkpoint inhibitors (ICIs). A major barrier to an effective anti-tumor immunity is the immunosuppressive tumor environment (TME), in which transforming growth factor-beta (TGF-β) plays a central role. TGF-β is produced as a latent complex with latency-associated protein (LAP) and requires proteolytic cleavage for activation.

Plasma kallikrein (PLK)-mediated cleavage of LAP releases bioactive TGF-β enabling receptor engagement and signaling. Biomarkers reflecting this TGF-β activation in the TME may provide insights into treatment response.

In this study we evaluated a serological biomarker of PLK-activated TGF-β (TGF-β-LAP) in patients with treatment-refractory metastatic PDAC receiving stereotactic body radiotherapy (SBRT) combined with ICIs in the CheckPAC trial.

Poster

Conclusion

Changes in circulating TGF-β-LAP associate with clinical outcomes in patients with metastatic PDAC that are treated with SBRT and ICIs whereas pre-treatment levels were not. Early increases (C2D1) in TGF-β-LAP identify patients with treatment resistance, supporting the use as a pharmacodynamic biomarker of immune suppression and (lack of) therapeutic response. In conclusion, these findings warrant further investigation of TGF-β-LAP as a biomarker for patient stratification and monitoring in immunotherapy-based treatment strategies and in trials targeting the TGF-β pathway.

Get in touch

Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.

What Drives Cardiovascular Disease?

Cardiovascular diseases are often the results of biological processes that have been developing for years. Deep inside the heart and blood vessels, inflammation, fibrosis, and tissue remodeling can already be active long before symptoms become evident been, influencing both disease progression and treatment response. This is why blood-based biomarkers are valuable, as they can identify active processes that may not be captured by conventional assessments alone.

Watch this video with our Director of Cardiovascular and Renal Research, Federica Genovese, to find out how our ECM biomarkers could enrich your next cardiovascular study.

Why does the ECM matter?

There are more than 330 different chronic diseases involving the extracellular matrix (ECM), and 40% of all people in the Western world live with an ECM disease, as we recently published in Lancet.

Watch this video to learn more about why quantifying the extracellular matrix is important in drug development and how our biomarkers can support your program.

Interested in discussing how our biomarkers could support your drug development program?